



For Immediate Release

February 12, 2010

Contact: Lee Southard: 239-410-2771

Developing Attack Against U.S. Number One Killer

In conjunction with National Heart Failure Awareness Week, VasoGenix, a Lenexa-based pharmaceutical company, announces major progress on its upcoming new drug to reduce and treat heart failure.

Heart failure is not only the #1 killer in America, it is the #1 hospital expense, the #1 reason for hospitalization, and the #1 diagnosis for people over 65.

VasoGenix is developing a new drug that combines the attributes of a potent vasodilator and a biodegradable controlled release delivery system. Plans are underway to test the drug at the nationally-renowned Cleveland Clinic. James Young, MD, who is Chairman of the Division of Medicine at the Cleveland Clinic, is working with VasoGenix and serves on its board.

Pre-clinical testing has shown that the new drug mimics the blood pressure-lowering of calcitonin gene related peptide (CGRP) but maintains or lowers heart rate. In addition, it precisely interacts with CGRP receptor sites located in the heart which are elevated in heart failure patients. The drug promises therapy that can be released over time to provide long term relief of heart failure symptoms.

The benefits of the compound, in addition to saving lives, may include decreased hospital stays, decreased hospital costs, and an enhanced quality of life.

For more information, please contact Dr. Lee Southard, Chairman and CEO, VasoGenix, Lenexa, Kansas, office 913-888-4773, cell 239-410-2771, southardl@earthlink.net.

###

VasoGenix Pharmaceuticals is a privately held, emerging biopharmaceutical company focused on developing cardiovascular drugs. The Company is focused initially on positioning its analog related to CGRP (calcitonin gene related peptide) as a front-line treatment for heart failure.

Statements contained in this press release, which are not historical facts, are forward-looking statements, as the term is defined in the Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by the use of words such as, "expects," "plans," "estimates," "projects," "promises," "intends," "believes," and similar expressions that do not relate to historical matters. Such forward-looking statements are subject to risks and uncertainties which can cause actual results to differ materially from those currently anticipated, due to a number of factors, which include, but are not limited to, to identify strategic partners or, if identified, the inability to enter into an acceptable agreement with such strategic partners and successfully concluding the development and regulatory processes. All forward-looking statements in this press release are made as of today, based upon information known to management as of the date hereof. VasoGenix assumes no obligation to update or revise any of its forward-looking statements even if experience or future changes show that indicated results or events will not be realized.